
|Videos|July 4, 2022
Dr. Garmezy on the evolving treatment paradigm for progressive urothelial malignancies
Author(s)Urology Times staff
“There has been a ton of activity in recent years with new FDA approvals,” says Benjamin Garmezy, MD.
Advertisement
In this video, Benjamin Garmezy, MD, discusses the expanding armamentarium for the treatment of patients with progressive urothelial malignancies. Garmezy is assistant director of Genitourinary Research at Sarah Cannon Research Institute at Tennessee Oncology.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5


















